Taisho Pharmaceuticals | Sustainability Performance
Researches, develops, and markets pharmaceutical and healthcare products, focusing on over-the-counter drugs, prescription medicines, and wellness solutions.
1912
Japan
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5969
Overallⓘ#289
in Japanⓘ#142
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Taisho Pharmaceutical Holdings Co Ltd, Japanese major OTC pharma (LipovitanD, Bridgemark), has faced sustained class actions over the contested 2023 USD 4.7 billion Uehara familyled takeprivate (USD 4.7 billion deal, Japan's largest historic management buyout) affecting Japanese institutional minority shareholders, plus periodic Japanese MHLW enforcement on inadequate disclosure.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.